RAINBOW - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.8
| Stock Code | RAINBOW | Market Cap | 13,766 Cr. | Current Price | 1,356 ₹ | High / Low | 1,646 ₹ |
| Stock P/E | 56.1 | Book Value | 156 ₹ | Dividend Yield | 0.22 % | ROCE | 18.3 % |
| ROE | 16.7 % | Face Value | 10.0 ₹ | DMA 50 | 1,264 ₹ | DMA 200 | 1,296 ₹ |
| Chg in FII Hold | -2.00 % | Chg in DII Hold | 1.63 % | PAT Qtr | 65.8 Cr. | PAT Prev Qtr | 73.2 Cr. |
| RSI | 66.8 | MACD | 31.1 | Volume | 1,27,742 | Avg Vol 1Wk | 1,33,002 |
| Low price | 1,009 ₹ | High price | 1,646 ₹ | PEG Ratio | 3.15 | Debt to equity | 0.46 |
| 52w Index | 54.5 % | Qtr Profit Var | -1.73 % | EPS | 24.2 ₹ | Industry PE | 47.8 |
📊 Financial Overview: Rainbow Children’s Medicare shows solid fundamentals with quarterly PAT at ₹65.8 Cr. vs ₹73.2 Cr. previously (-1.73% variation). ROE at 16.7% and ROCE at 18.3% highlight efficient capital utilization. Debt-to-equity ratio of 0.46 is moderate, ensuring financial stability. EPS of ₹24.2 is decent, supported by consistent profitability, though margins show slight pressure.
💰 Valuation Indicators: Current P/E of 56.1 is higher than the industry average of 47.8, suggesting premium valuation. P/B ratio of ~8.7 (₹1,356 / ₹156) reflects expensive pricing. PEG ratio of 3.15 indicates growth is priced in at stretched levels. Intrinsic value appears lower than current market price, leaving limited margin of safety for new investors.
🏢 Business Model & Competitive Advantage: Rainbow operates in pediatric and maternity healthcare, with strong brand recognition and specialized services. Its competitive advantage lies in niche focus, quality care, and expanding hospital network. Government-backed healthcare demand and rising awareness support growth, though valuations remain stretched.
📈 Entry Zone & Holding Guidance: Considering premium valuations, an attractive entry zone lies between ₹1,200–₹1,250 (near DMA 200 support). Long-term investors may hold for exposure to healthcare growth, but fresh entry at current levels carries valuation risk.
Positive
- 🌟 Strong [ROCE](ca://s?q=Explain_ROCE) at 18.3% and [ROE](ca://s?q=Explain_ROE) at 16.7%
- 📈 Specialized niche in pediatric and maternity healthcare
- 💡 Expanding hospital network strengthens brand presence
- 🛡️ Moderate [debt-to-equity](ca://s?q=Debt_to_equity_ratio_explained) ratio of 0.46
Limitation
- ⚠️ High [P/E ratio](ca://s?q=Explain_P/E_ratio) compared to industry peers
- 📉 PEG ratio of 3.15 indicates stretched valuation
- 🔎 EPS of 24.2 is modest relative to price
- 📊 Profit contraction (-1.73%) in latest quarter
Company Negative News
- 📉 Decline in FII holdings (-2.00%)
- ⚠️ Concerns over stretched valuations and profit contraction
Company Positive News
- 📈 Increase in DII holdings (+1.63%) shows domestic investor confidence
- 💰 Strong brand positioning in specialized healthcare
Industry
🏥 The healthcare industry trades at an average P/E of 47.8. Rainbow’s P/E of 56.1 highlights premium valuation. Industry growth is supported by rising healthcare demand, specialized services, and government initiatives, but profitability remains sensitive to operational costs and expansion expenses.
Conclusion
✅ Rainbow Children’s Medicare offers strong return metrics, niche specialization, and expanding presence in pediatric and maternity healthcare. However, premium valuations and modest EPS make fresh entry unattractive at current levels. Entry around ₹1,200–₹1,250 provides a better risk-reward balance. Long-term holding is suitable for investors seeking exposure to healthcare growth, with cautious monitoring of earnings consistency.
Would you like me to extend this with a peer comparison or a healthcare sector outlook for deeper insights?